论文部分内容阅读
目的了解多重耐药鲍曼不动杆菌耐药谱和特点。方法分析2004年6月至2006年12月来自住院患者标本的鲍曼不动杆菌耐药性资料及其治疗情况。结果从192株标本中分离出181株多重耐药鲍曼不动杆菌,对头孢哌酮/舒巴坦耐药率最低(25·41%),其次是亚胺培南(38·12%)。结论对多重耐药鲍曼不动杆菌感染的患者应以亚胺培南/西司他汀和β-内酰胺酶抗菌抑制剂作为第一线抗菌药物。病情严重尤其是全耐药时可联合用药,可提高疗效。
Objective To understand the drug resistance spectrum and characteristics of multidrug-resistant Acinetobacter baumannii. Methods The data and treatment of Acinetobacter baumannii from inpatients from June 2004 to December 2006 were analyzed. Results 181 strains of multidrug-resistant Acinetobacter baumannii isolated from 192 strains showed the lowest resistance rate to cefoperazone / sulbactam (25.41%), followed by imipenem (38.12%), . Conclusion In patients with multidrug-resistant Acinetobacter baumannii infection, imipenem / cilastatin and β-lactamase antibacterial inhibitors should be the first-line antimicrobial agents. Serious illness, especially all drug resistance can be combined with medication, can improve the curative effect.